The document discusses surgical site infections (SSIs). Some key points:
- SSIs are the third most common type of hospital-acquired infection, accounting for 14-16% of infections. They are also the most common infection in surgical patients, observed in 38% of cases.
- Risk factors for SSIs include patient characteristics like diabetes or obesity, as well as surgical factors like long operation time or inadequate sterilization of instruments.
- Prevention strategies focus on proper use of antimicrobial prophylaxis, maintaining normothermia, controlling blood glucose, and following guidelines on skin/wound care before, during and after surgery.
Preventing Infection during Surgery is important. Standard Guidelines help team work on the same page. An update on various preventive strategy is discussed.
Preventing Infection during Surgery is important. Standard Guidelines help team work on the same page. An update on various preventive strategy is discussed.
Prevention of Surgical Site Infection- SSI [compatibility mode]drnahla
Infection Control Guidelines for Prevention of Surgical Site Infection- SSI
Dr. NAHLA ABDEL KADERوMD, PhD.
INFECTION CONTROL CONSULTANT, MOH
INFECTION CONTROL CBAHI SURVEYOR
Infection Control Director, KKH.
Objectives:
•Learn about the current of SSI prevention in Canada
•Review the updated SSI-GSK
•Compare CPSI SSI-GSK to national and international literature
Prevention of Surgical Site Infection- SSI [compatibility mode]drnahla
Infection Control Guidelines for Prevention of Surgical Site Infection- SSI
Dr. NAHLA ABDEL KADERوMD, PhD.
INFECTION CONTROL CONSULTANT, MOH
INFECTION CONTROL CBAHI SURVEYOR
Infection Control Director, KKH.
Objectives:
•Learn about the current of SSI prevention in Canada
•Review the updated SSI-GSK
•Compare CPSI SSI-GSK to national and international literature
Hear firsthand from Healthcare Improvement Scotland and one of their teams that participated in the U.K. Health Foundation collaborative about their experience in applying the Vincent Framework at the frontline. The related challenges and benefits and how it has impacted their work.
A discussion on the risk factors, classification and clinical presentation of surgical site infection. Also elucidates the overview of management approach to SSI.
According to the National Center for Health Statistics, approximately 46 million surgical procedures are performed annually in the United States, the majority of which are done in an outpatient setting.1
Infection is the most common complication of surgery.2
Surgical site infections (SSIs) occur in approximately 3% to 6% of
patients and prolong hospitalization by an average of 7 days at a direct annual cost of $5 to $10 billion.3,4
SSIs are the third (14%–16%) most frequent cause of nosocomial infections among hospitalized patients.3
Infection occurs within 30 days after the operative procedure if no implant is left in place or within 1 year if implant is in place and the infection appears to be related to the operative procedure
risk factors includes
Age
Obesity
Diabetes
Malnutrition
Prolonged preoperative stay
Infection at remote site
Systemic steroid use
Nicotine use
Surgical site Infection during Internship in medical college.pptxrautkrisna
Infections that occur in the wound created by an invasive surgical procedure are generally referred to as surgical site infections (SSIs). SSIs are one of the most important causes of healthcare-associated infections (HCAIs). A prevalence survey undertaken in 2006 suggested that approximately 8% of patients in hospital in the UK have an HCAI. SSIs accounted for 14% of these infections and nearly 5% of patients who had undergone a surgical procedure were found to have developed an SSI. However, prevalence studies tend to underestimate SSI because many of these infections occur after the patient has been discharged from hospital. SSIs are associated with considerable morbidity and it has been reported that over one-third of postoperative deaths are related, at least in part, to SSI. However, it is important to recognise that SSIs can range from a relatively trivial wound discharge with no other complications to a life-threatening condition. Other clinical outcomes of SSIs include poor scars that are cosmetically unacceptable, such as those that are spreading, hypertrophic or keloid, persistent pain and itching, restriction of movement, particularly when over joints, and a significant impact on emotional wellbeing. SSI can double the length of time a patient stays in hospital and thereby increase the costs of health care. Additional costs attributable to SSI of between 814 and 6626 have been reported depending on the type of surgery and the severity of the infection. The main additional costs are related to re-operation, extra nursing care and interventions, and drug treatment costs. The indirect costs, due to loss of productivity, patient dissatisfaction and litigation, and reduced quality of life, have been studied less extensively.Infections that occur in the wound created by an invasive surgical procedure are generally referred to as surgical site infections (SSIs). SSIs are one of the most important causes of healthcare-associated infections (HCAIs). A prevalence survey undertaken in 2006 suggested that approximately 8% of patients in hospital in the UK have an HCAI. SSIs accounted for 14% of these infections and nearly 5% of patients who had undergone a surgical procedure were found to have developed an SSI. However, prevalence studies tend to underestimate SSI because many of these infections occur after the patient has been discharged from hospital. SSIs are associated with considerable morbidity and it has been reported that over one-third of postoperative deaths are related, at least in part, to SSI. However, it is important to recognise that SSIs can range from a relatively trivial wound discharge with no other complications to a life-threatening condition. Other clinical outcomes of SSIs include poor scars that are cosmetically unacceptable, such as those that are spreading, hypertrophic or keloid, persistent pain and itching, restriction of movement, particularly when over joints, and a significant impact on emotional wllbeing
Infection Prevention and Control in Hospitals by Dr DeleKemi Dele-Ijagbulu
Infection prevention and control is everybody's business! It is an essential, though often under-recognised and under supported part of the infrastructure of health care. However it saves lives and prevents avoidable morbidity and mortality. This presentation highlights the importance and the practical components of infection prevention and control in the hospital setting.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
2. • The third most common type of nosocomial
infection accounting for 14% to 16% of all
infections
• Among surgical patients, SSIs are the most
common nosocomial infection, observed in 38% of
cases.
• Two-thirds of these infections are due to the
incision, whereas one-third are due to infection of
the organs or spaces during surgery.
Surgical Site Infections
Mangram AJ et al. Infect Control Hosp Epidemiol. 1999;20:250-278.
3. • Infections of the tissues, organs, or spaces
exposed by surgeons during performance of an
invasive procedure.
• Infections occurring up to 30 or 90 days after
surgery as per CDC definition 2015 and affecting
either the incision or deep tissue at the operation
site.
• Surgical sites are considered infected when there
are signs of systemic and local inflammation and
bacterial counts are 105 cfu/mL or higher.
Infections are also differentiated by purulence or
nonpurulence.
Surgical Site Infections
4.
5.
6.
7.
8. CDC Classification of SSI (Within 30 Days of
Operation, Within 1 Year if Implant in Place)
Surgical Site Infections
SSI
Mortality
Morbidity
LOS
Cost
9. • Patient flora (Skin, Mucous
membranes, GI tract)
• Seeding from a distant focus of
infection
Endogenous
• Surgical team (Soiled attire, Breaks in aseptic
technique, Inadequate hand hygiene)
• OR environment & ventilation
• Tools, equipment, materials in OR
Exogenous
Surgical Site Infections Pathogenesis
10.
11. Surgical Site Infections Risk Factors
Surgical
Techniques
& Surgical
Drains
Skin
Antisepsis
& Body
Temp.
OR
Ventilation
Preoper-
ative
shaving
Inadequate
Instruments
Sterilization
Prophyla-
ctic
Antibiotic
Duration of
Surgery &
Surgical
Scrub
Operation
Factors
13. • Lack of standardized methods for post-
discharge/outpatient surveillance with the
increased number of outpatient surgeries
• Increasing trend toward resistant
organisms may undermine the
effectiveness of existing
recommendations for antimicrobial
prophylaxis
Surgical Site Infections Challenges
14. Core Strategies
High levels of scientific evidence
Demonstrated feasibility
Supplemental
Strategies
Some scientific evidence
Variable levels of feasibility
Surgical Site Infections
Prevention Strategies
Most core and supplemental strategies are based on HICPAC guidelines. Strategies that are not
included in HICPAC guidelines will be noted by an asterisk (*) after the strategy. HICPAC
guidelines may be found at www.cdc.gov/hicpac
15. Administer antimicrobial prophylaxis in
accordance with evidence based standards and
guidelines
• Administer within 1 hour prior to incision*
• 2hr for vancomycin and fluoroquinolones
• Select appropriate agents on basis of
• Surgical procedure
• Most common SSI pathogens for the procedure
• Published recommendations
*Fry DE. Surgical Site Infections and the Surgical Care Improvement Project (SCIP): Evolution of National Quality Measures.
Surg Infect 2008;9(6):579-84.
Surgical Site Infections
Prevention Strategies: Core
Preoperative Measures
16. Remote infections-whenever possible:
• Identify and treat before elective operation
• Postpone operation until infection has resolved
Do not remove hair at the operative site unless it
will interfere with the operation; do not use
razors
• If necessary, remove by clipping or by use of a
depilatory agent
Surgical Site Infections
Prevention Strategies: Core
Preoperative Measures
17. Skin Prep
• Use appropriate antiseptic agent and technique for skin
preparation
Maintain immediate postoperative normothermia*
Colorectal surgery patients
• Mechanically prepare the colon (Enemas, cathartic
agents)
• Administer non-absorbable oral antimicrobial agents in
divided doses on the day before the operation
Surgical Site Infections
Prevention Strategies: Core
Preoperative Measures
*Fry DE. Surgical Site Infections and the Surgical Care Improvement Project (SCIP): Evolution of National
Quality Measures. Surg Infect 2008;9(6):579-84.
18. Operating Room (OR) Traffic
• Keep OR doors closed during surgery except as
needed for passage of equipment, personnel, and the
patient
Surgical Site Infections
Prevention Strategies: Core
Intraoperative Measures
19. Surgical Site Infections
Prevention Strategies: Core
Postoperative Measures
Surgical Wound Dressing
• Protect primary closure incisions with sterile dressing for 24-48
hrs post-op
Control blood glucose level during the immediate post-
operative period (cardiac)*
• Measure blood glucose level at 6AM on POD#1 and #2 with
procedure day = POD#0
• Maintain post-op blood glucose level at <200mg/dL
Discontinue antibiotics within 24hrs after surgery end
time (48hrs for cardiac)*
*Fry DE. Surgical Site Infections and the Surgical Care Improvement Project (SCIP): Evolution of National
Quality Measures. Surg Infect 2008;9(6):579-84.
20. Nasal screen and decolonize only
Staphylococcus aureus carriers undergoing
elective cardiac and other procedures (i.e.,
orthopaedic, neurosurgery procedures with
implants) with preoperative mupirocin therapy*
Bode LGM, etal. Preventing SSI in nasal carriers of Staph aureus. NEJM 2010;362:9-17
Screen preoperative blood glucose levels and
maintain tight glucose control POD#1 and POD#2
in patients undergoing select elective
procedures (e.g., arthroplasties, spinal fusions)*
Surgical Site Infections
Prevention Strategies:
Supplemental Preoperative
Measures
NOTE: These supplemental strategies are not part of the 1999 HICPAC Guideline for Prevention of Surgical Site Infections
21. Surgical Site Infections
Prevention Strategies:
Supplemental Perioperative
Measures
Re-dose antibiotic at the 3 hr interval in procedures
with duration >3hrs *
See exceptions to this recommendation in Engelman R, et al. The Society of Thoracic Surgeons Practice Guideline Series:Antibiotic
Prophylaxis in Cardica Surgery, Part II:Antibiotic Choice. Ann Thor Surg 2007;83:1569-76
Adjust antimicrobial prophylaxis dose for obese
patients (body mass index >30)*
Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol
2008;29 (Suppl 1):S51-S61
Use at least 50% fraction of inspired oxygen
intraoperatively and immediately postoperatively in
select procedure(s)*
Maragakis LL, Cosgrove SE, Martinez EA, et al. Intraoperative fraction of inspired oxygen is a modifiable risk factor for surgical site
infection after spinal surgery. Anesthesiology 2009;110:556-562. and
Meyhoff CS, Wetterslev J, Jorgensen LN, et al. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary
complications after abdominal surgery: The PROXI randomized clinical trial. JAMA 2009;302:1543-1550.
22. Feedback of surgeon specific infection rates.
Surgical Site Infections
Prevention Strategies:
Supplemental Postoperative
Measures